Form 4: Lilly Endowment Inc. Sells Shares in Eli Lilly & Co.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., has sold a portion of its holdings in multiple transactions on February 9, 2024.

Summary

• Lilly Endowment Inc. sold a total of 206,257 shares of Eli Lilly & Co. common stock on February 9, 2024.
• The sales were executed in multiple transactions at varying weighted average prices.
• The prices ranged from $740.266 to $745.24 per share.
• Following these transactions, Lilly Endowment Inc. beneficially owns 99,118,810 shares of Eli Lilly & Co.

Sentiment

Score: 5

Explanation: The document is a neutral disclosure of a share sale, with no indication of positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of a significant shareholder's transactions and is a normal part of market operations.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and large shareholders in publicly traded companies.
• The transaction is similar to other large shareholders selling shares in the open market.
• The volume of shares sold is not unusual for a large institutional investor like Lilly Endowment Inc.

Stakeholder Impact

• The share sale may have a minor impact on the stock price of Eli Lilly & Co., but is unlikely to be significant given the large number of shares outstanding.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, share sale, stock transaction, beneficial ownership, Form 4